Renal artery obstruction

Summary

Renal artery obstruction (MONDO:0006945) is a disease and 12 clinical trials. Top therapeutic interventions include candesartan cilexetil and elamipretide hydrochloride. A subtype of renal artery disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	renal artery obstruction
Mondo ID	MONDO:0006945
EFO	EFO:1001150
MeSH	D012078
DOID	DOID:2972
UMLS	C0035066
MedGen	48406
Is cancer (heuristic)	no

Disease family

This is a subtype of renal artery disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › renal artery disease › renal artery obstruction

Related subtypes (2): renal artery atheroma, nephrosclerosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Candesartan Cilexetil	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cyclosporine, Rosuvastatin, Sodium Chloride.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	4
Not specified	4
PHASE2/PHASE3	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00081731	PHASE3	COMPLETED	Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
NCT00150943	PHASE3	COMPLETED	Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis
NCT00180544	PHASE3	TERMINATED	Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease
NCT00868972	PHASE2/PHASE3	UNKNOWN	Renal Stenting With Distal Atheroembolic Protection
NCT01344460	PHASE3	COMPLETED	Gadobutrol Enhanced MRA of the Renal Arteries
NCT03521700	PHASE2/PHASE3	COMPLETED	Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement
NCT01755858	PHASE1/PHASE2	TERMINATED	Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
NCT00027469	PHASE1	COMPLETED	MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery
NCT02770066	Not specified	RECRUITING	A Prospective Danish National Registry of PTRA in Patients With Renovascular Hypertension
NCT00490841	Not specified	COMPLETED	The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis
NCT03080519	Not specified	UNKNOWN	Endovascular Therapy for Renal Artery Stenosis in China
NCT03530748	Not specified	UNKNOWN	On-table Renal Perfusion Evaluation Renal Artery Stenosis or Obstruction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CANDESARTAN CILEXETIL	4	1
ELAMIPRETIDE HYDROCHLORIDE	1	1
CHEMBL1357356	0	1